Related Experiment Videos
Update on nonalcoholic fatty liver disease
1Division of Gastroenterology and the Robert Schwartz Center of Metabolism and Nutrition at MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio 44109-1998, USA. ajm3@po.cwru.edu
Journal of Clinical Gastroenterology
|March 2, 2002
Summary
Nonalcoholic fatty liver disease (NAFLD) is common, especially in those with obesity or diabetes. Nonalcoholic steatohepatitis (NASH), a severe form, can lead to cirrhosis and liver death, necessitating targeted therapies.
Area of Science:
- Hepatology
- Gastroenterology
- Internal Medicine
Background:
- Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver condition in the U.S.
- It affects 5% of the general population and up to 75% of individuals with obesity and type II diabetes.
- NAFLD encompasses a spectrum from benign hepatic steatosis to progressive nonalcoholic steatohepatitis (NASH).
Purpose of the Study:
- To review the epidemiology, pathophysiology, and clinical outcomes of NAFLD and NASH.
- To discuss diagnostic methods, particularly liver biopsy for prognostic information.
- To outline current and future therapeutic strategies for NASH.
Main Methods:
- Literature review of NAFLD and NASH prevalence, risk factors, and disease progression.
- Analysis of the two-step pathophysiology involving insulin resistance and oxidative stress.
- Evaluation of treatment modalities, including comorbidity management and pharmacotherapy.
Main Results:
- NASH progresses to cirrhosis in 25% and liver-related death in 10% of patients.
- Obesity, type II diabetes, and hyperlipidemia are key comorbidities.
- Ursodeoxycholic acid shows promise, while vitamin E has limited benefit.
Conclusions:
- NAFLD is a significant public health issue with potentially severe outcomes.
- Effective management requires addressing underlying metabolic derangements.
- Future research should focus on understanding pathophysiology to develop antifibrotic therapies.